This study uncovered that lysine methylated NFAT5, an osmoprotective responsive transcription factor, is a determinant of EGFR-driven tumor progression and the response to TMZ in GBM, reinforcing the key role of lysine methylation of non-histone proteins and demonstrating its potential as a therapeutic target. Here, NFAT5 is linked to glioblastoma.